Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Relapsed/Refractory and Treatment-naïve Deletion 17p CLL/SLL
NCT02337829Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Jan 2015
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Acerta Pharma. Started Jan 2015; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02337829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337829.